Hero bg image

Advancing a New Era of CNS Therapeutics

Utilizing our unique di si-RNA platform, Atalanta Therapeutics is dedicated to finding solutions for intractable diseases of the central nervous system. Our pipeline is composed of programs addressing diseases with significant unmet need with the potential to improve the lives of millions of patients around the world.

Disease Area stage in the processDisease Area

Target stage in the processTarget

Discovery stage in the processDiscovery

Pre-Clinical stage in the processPre-Clinical

IND Enabling stage in the processIND Enabling

Phase 1 stage in the processPhase 1

Product Rights stage in the processProduct Rights

Epilepsy

KCNT1 (ATL-201)

Genetic Epilepsy

KCNT1 (ATL-201) progress: 55%

Huntington’s Disease

Pan HTT (ATL-101)

Huntington’s Disease

Pan HTT (ATL-101) progress: 50%

MSH3

Huntington’s Disease

MSH3 progress: 25%

Pain

NAV 1.7 (ATL-301)

Multiple Indications

NAV 1.7 (ATL-301) progress: 30%

Alzheimer’s Disease

APOE

Alzheimer’s Disease

APOE progress: 25%

CD33

Alzheimer’s Disease

CD33 progress: 25%

CNS Disorders

Undisclosed

Multiple Targets

Undisclosed progress: 25%
Background Image
Logo Image

CNS Disorders

Undisclosed

Multiple Targets

Undisclosed progress: 35%
Background Image
Logo Image
Your browser is out of date!

Update your browser to view this website correctly. Update my browser now